These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22143528)

  • 1. A physiologically based pharmacokinetic model for capreomycin.
    Reisfeld B; Metzler CP; Lyons MA; Mayeno AN; Brooks EJ; Degroote MA
    Antimicrob Agents Chemother; 2012 Feb; 56(2):926-34. PubMed ID: 22143528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
    Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physiologically based pharmacokinetic model of rifampin in mice.
    Lyons MA; Reisfeld B; Yang RS; Lenaerts AJ
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1763-71. PubMed ID: 23357766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.
    Garcia-Contreras L; Fiegel J; Telko MJ; Elbert K; Hawi A; Thomas M; VerBerkmoes J; Germishuizen WA; Fourie PB; Hickey AJ; Edwards D
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2830-6. PubMed ID: 17517845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
    Garcia-Prats AJ; Schaaf HS; Hesseling AC
    Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.
    Wendling T; Tsamandouras N; Dumitras S; Pigeolet E; Ogungbenro K; Aarons L
    AAPS J; 2016 Jan; 18(1):196-209. PubMed ID: 26538125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.
    Srivastava S; Pasipanodya JG; Meek C; Leff R; Gumbo T
    J Infect Dis; 2011 Dec; 204(12):1951-9. PubMed ID: 22021624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.
    Lee SH; Shin J; Choi JM; Lee EY; Kim DH; Suh JW; Chang JH
    Int J Antimicrob Agents; 2003 Jul; 22(1):81-3. PubMed ID: 12842334
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification.
    Chou WC; Lin Z
    Environ Int; 2019 Aug; 129():408-422. PubMed ID: 31152982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition.
    Nong A; Tan YM; Krolski ME; Wang J; Lunchick C; Conolly RB; Clewell HJ
    J Toxicol Environ Health A; 2008; 71(20):1363-81. PubMed ID: 18704829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capreomycin oleate microparticles for intramuscular administration: Preparation, in vitro release and preliminary in vivo evaluation.
    Cambronero-Rojas A; Torres-Vergara P; Godoy R; von Plessing C; Sepúlveda J; Gómez-Gaete C
    J Control Release; 2015 Jul; 209():229-37. PubMed ID: 25956458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
    Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
    J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction topology of Mycobacterium tuberculosis genes response to capreomycin and novel clues for more drug targets.
    Zheng F; Xie J
    J Cell Biochem; 2011 Oct; 112(10):2716-20. PubMed ID: 21678479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
    Allen BC; Hack CE; Clewell HJ
    Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
    Yew WW
    Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.